The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-$γ$ release assays: a systematic review and meta-analysis. Krutikov, M., Faust, L., Nikolayevskyy, V., Hamada, Y., Gupta, R. K, Cirillo, D., Mateelli, A., Korobitsyn, A., Denkinger, C. M, & Rangaka, M. X The Lancet Infectious Diseases, 22(2):250–264, Elsevier, oct, 2022.
The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-$γ$ release assays: a systematic review and meta-analysis [link]Paper  doi  abstract   bibtex   
Summary Background Novel skin-based tests for tuberculosis infection might present suitable alternatives to current tests; however, diagnostic performance of new tests compared with the purified protein derivative-tuberculin skin test (TST) or interferon-$γ$ release assays (IGRA) needs systematic assessment. Methods In this systematic review and meta-analysis, we searched English (Medline OVID), Chinese (Chinese Biomedical Literature Database and the China National Knowledge Infrastructure), and Russian (e-library) databases from the inception of each database to May 15, 2019, (with updated search of the Russian and English databases on Oct, 20 2020) using terms "ESAT6" OR "CFP10" AND "skin test" AND "Tuberculosis" OR "C-Tb" OR "Diaskintest". We included studies reporting on the performance of index tests alone or compared with a comparator. Inclusion criteria varied according to review objectives and performance outcome, but reporting of test cut-offs for positivity applied to study population was required from all studies. We used a hierarchy of reference standards for tuberculosis infection consistent with the 2020 WHO framework to evaluate diagnostic performance. Two authors independently reviewed the titles and abstracts for English and Chinese (LF and MK) and Russian studies (MK and VN). Study quality was assessed with QUADAS-2. Pooled random-effects estimates are presented when appropriate for total agreement proportion, sensitivity in microbiologically confirmed tuberculosis and specificity in cohorts with low risk of tuberculosis infection. This study is registered with PROSPERO, CRD42019135572. Findings We identified 1466 original articles, of which 37 (2˙5%) studies, including 10 915 individuals (7111 Diaskintest, 2744 C-Tb, 887 EC, 173 DPPD), were included in the qualitative analysis (29 [78%] studies of Diaskintest, five [15%] studies of C-Tb, two [5%] studies of EC-skintest, and one [3%] study of DPPD). 22 (1˙5%) studies including 5810 individuals (3143 Diaskintest, 2129 C-Tb, 538 EC-skintest) were included in the quantitative analysis: 15 (68%) of Diaskintest, five (23%) of C-Tb, and two (9%) of EC-skintest. Tested sub-populations included individuals with HIV, children (0–18 years), and individuals exposed to tuberculosis. Studies were heterogeneous with moderate to high risk of bias. Nine head-to-head studies of index test versus TST and IGRA permitted direct comparisons and pooling. In a mixed cohort of people with and without tuberculosis, Diaskintest pooled agreement with IGRA was 87˙16% (95% CI 79˙47–92˙24) and 55˙45% (46˙08–64˙45) with TST-5 mm cut-off (TST5 mm). Diaskintest sensitivity was 91˙18% (95% CI 81˙72–95˙98) compared with 88˙24% (78˙20–94˙01) for TST5 mm, 89˙66 (78˙83–95˙28) for IGRA QuantiFERON, and 90˙91% (79˙95–96˙16) for TSPOT.TB. C-Tb agreement with IGRA in individuals with active tuberculosis was 79˙80% (95% CI 76˙10–83˙07) compared with 78˙92% (74˙65–82˙63) for TST5 mm/15 mm cut-off (TST5 mm/15 mm). TST5/15mm reflects threshold in cohorts that applied stratified cutoffs: 5 mm for HIV-infected, immunocompromised, or BCG-naive individuals, and 15mm for BCG-vaccinated immunocompetent individuals. C-Tb sensitivity was 74˙52% (95% CI 70˙39–78˙25) compared with a sensitivity of 78˙18% (67˙75–85˙94) for TST5 mm/15 mm, and 71˙67% (63˙44–78˙68) for IGRA. Specificity was 97˙85% (95% CI 93˙96–99˙25) for C-Tb versus 93˙31% (90˙22–95˙48) for TST 15 mm cut-off and 99˙15% (79˙66–99˙97) for IGRA. EC-skintest sensitivity was 86˙06% (95% CI 82˙39–89˙07). Interpretation Novel skin-based tests for tuberculosis infection appear to perform similarly to IGRA or TST; however, study quality varied. Evaluation of test performance, patient-important outcomes, and diagnostic use in current clinical algorithms will inform implementation in key populations. Funding StopTB (New Diagnostics Working Group) and FIND. Translations For the Chinese and Russian translations of the abstract see Supplementary Materials section.
@article{Krutikov2021,
abstract = {Summary Background Novel skin-based tests for tuberculosis infection might present suitable alternatives to current tests; however, diagnostic performance of new tests compared with the purified protein derivative-tuberculin skin test (TST) or interferon-$\gamma$ release assays (IGRA) needs systematic assessment. Methods In this systematic review and meta-analysis, we searched English (Medline OVID), Chinese (Chinese Biomedical Literature Database and the China National Knowledge Infrastructure), and Russian (e-library) databases from the inception of each database to May 15, 2019, (with updated search of the Russian and English databases on Oct, 20 2020) using terms "ESAT6" OR "CFP10" AND "skin test" AND "Tuberculosis" OR "C-Tb" OR "Diaskintest". We included studies reporting on the performance of index tests alone or compared with a comparator. Inclusion criteria varied according to review objectives and performance outcome, but reporting of test cut-offs for positivity applied to study population was required from all studies. We used a hierarchy of reference standards for tuberculosis infection consistent with the 2020 WHO framework to evaluate diagnostic performance. Two authors independently reviewed the titles and abstracts for English and Chinese (LF and MK) and Russian studies (MK and VN). Study quality was assessed with QUADAS-2. Pooled random-effects estimates are presented when appropriate for total agreement proportion, sensitivity in microbiologically confirmed tuberculosis and specificity in cohorts with low risk of tuberculosis infection. This study is registered with PROSPERO, CRD42019135572. Findings We identified 1466 original articles, of which 37 (2{\textperiodcentered}5{\%}) studies, including 10 915 individuals (7111 Diaskintest, 2744 C-Tb, 887 EC, 173 DPPD), were included in the qualitative analysis (29 [78{\%}] studies of Diaskintest, five [15{\%}] studies of C-Tb, two [5{\%}] studies of EC-skintest, and one [3{\%}] study of DPPD). 22 (1{\textperiodcentered}5{\%}) studies including 5810 individuals (3143 Diaskintest, 2129 C-Tb, 538 EC-skintest) were included in the quantitative analysis: 15 (68{\%}) of Diaskintest, five (23{\%}) of C-Tb, and two (9{\%}) of EC-skintest. Tested sub-populations included individuals with HIV, children (0–18 years), and individuals exposed to tuberculosis. Studies were heterogeneous with moderate to high risk of bias. Nine head-to-head studies of index test versus TST and IGRA permitted direct comparisons and pooling. In a mixed cohort of people with and without tuberculosis, Diaskintest pooled agreement with IGRA was 87{\textperiodcentered}16{\%} (95{\%} CI 79{\textperiodcentered}47–92{\textperiodcentered}24) and 55{\textperiodcentered}45{\%} (46{\textperiodcentered}08–64{\textperiodcentered}45) with TST-5 mm cut-off (TST5 mm). Diaskintest sensitivity was 91{\textperiodcentered}18{\%} (95{\%} CI 81{\textperiodcentered}72–95{\textperiodcentered}98) compared with 88{\textperiodcentered}24{\%} (78{\textperiodcentered}20–94{\textperiodcentered}01) for TST5 mm, 89{\textperiodcentered}66 (78{\textperiodcentered}83–95{\textperiodcentered}28) for IGRA QuantiFERON, and 90{\textperiodcentered}91{\%} (79{\textperiodcentered}95–96{\textperiodcentered}16) for TSPOT.TB. C-Tb agreement with IGRA in individuals with active tuberculosis was 79{\textperiodcentered}80{\%} (95{\%} CI 76{\textperiodcentered}10–83{\textperiodcentered}07) compared with 78{\textperiodcentered}92{\%} (74{\textperiodcentered}65–82{\textperiodcentered}63) for TST5 mm/15 mm cut-off (TST5 mm/15 mm). TST5/15mm reflects threshold in cohorts that applied stratified cutoffs: 5 mm for HIV-infected, immunocompromised, or BCG-naive individuals, and 15mm for BCG-vaccinated immunocompetent individuals. C-Tb sensitivity was 74{\textperiodcentered}52{\%} (95{\%} CI 70{\textperiodcentered}39–78{\textperiodcentered}25) compared with a sensitivity of 78{\textperiodcentered}18{\%} (67{\textperiodcentered}75–85{\textperiodcentered}94) for TST5 mm/15 mm, and 71{\textperiodcentered}67{\%} (63{\textperiodcentered}44–78{\textperiodcentered}68) for IGRA. Specificity was 97{\textperiodcentered}85{\%} (95{\%} CI 93{\textperiodcentered}96–99{\textperiodcentered}25) for C-Tb versus 93{\textperiodcentered}31{\%} (90{\textperiodcentered}22–95{\textperiodcentered}48) for TST 15 mm cut-off and 99{\textperiodcentered}15{\%} (79{\textperiodcentered}66–99{\textperiodcentered}97) for IGRA. EC-skintest sensitivity was 86{\textperiodcentered}06{\%} (95{\%} CI 82{\textperiodcentered}39–89{\textperiodcentered}07). Interpretation Novel skin-based tests for tuberculosis infection appear to perform similarly to IGRA or TST; however, study quality varied. Evaluation of test performance, patient-important outcomes, and diagnostic use in current clinical algorithms will inform implementation in key populations. Funding StopTB (New Diagnostics Working Group) and FIND. Translations For the Chinese and Russian translations of the abstract see Supplementary Materials section.},
author = {Krutikov, Maria and Faust, Lena and Nikolayevskyy, Vladyslav and Hamada, Yohhei and Gupta, Rishi K and Cirillo, Daniela and Mateelli, Alberto and Korobitsyn, Alexei and Denkinger, Claudia M and Rangaka, Molebogeng X},
doi = {10.1016/S1473-3099(21)00261-9},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Krutikov et al. - 2022 - The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified.pdf:pdf},
issn = {1473-3099},
journal = {The Lancet Infectious Diseases},
keywords = {fund{\_}not{\_}ack,review},
mendeley-tags = {fund{\_}not{\_}ack,review},
month = {oct},
number = {2},
pages = {250--264},
publisher = {Elsevier},
title = {{The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-$\gamma$ release assays: a systematic review and meta-analysis}},
url = {http://www.thelancet.com/article/S1473309921002619/fulltext http://www.thelancet.com/article/S1473309921002619/abstract https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00261-9/abstract},
volume = {22},
year = {2022}
}

Downloads: 0